- Home
- DH vs CRDF Comparison
DH vs CRDF Comparison
Compare DH & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DH
- CRDF
- Stock Information
- Founded
- DH 2011
- CRDF 1999
- Country
- DH United States
- CRDF United States
- Employees
- DH N/A
- CRDF 33
- Industry
- DH Computer Software: Prepackaged Software
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DH Technology
- CRDF Health Care
- Exchange
- DH Nasdaq
- CRDF Nasdaq
- Market Cap
- DH 280.0M
- CRDF 233.5M
- IPO Year
- DH 2021
- CRDF N/A
- Fundamental
- Price
- DH $4.15
- CRDF $4.10
- Analyst Decision
- DH Hold
- CRDF Strong Buy
- Analyst Count
- DH 10
- CRDF 6
- Target Price
- DH $5.10
- CRDF $11.92
- AVG Volume (30 Days)
- DH 769.5K
- CRDF 1.5M
- Earning Date
- DH 08-04-2025
- CRDF 08-07-2025
- Dividend Yield
- DH N/A
- CRDF N/A
- EPS Growth
- DH N/A
- CRDF N/A
- EPS
- DH N/A
- CRDF N/A
- Revenue
- DH $247,913,000.00
- CRDF $587,000.00
- Revenue This Year
- DH N/A
- CRDF N/A
- Revenue Next Year
- DH $1.66
- CRDF N/A
- P/E Ratio
- DH N/A
- CRDF N/A
- Revenue Growth
- DH N/A
- CRDF N/A
- 52 Week Low
- DH $2.15
- CRDF $2.01
- 52 Week High
- DH $6.17
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- DH 70.72
- CRDF 66.57
- Support Level
- DH $3.96
- CRDF $3.07
- Resistance Level
- DH $4.23
- CRDF $3.24
- Average True Range (ATR)
- DH 0.16
- CRDF 0.23
- MACD
- DH 0.01
- CRDF 0.06
- Stochastic Oscillator
- DH 86.27
- CRDF 92.98
About DH Definitive Healthcare Corp.
Definitive Healthcare Corp is a provider of healthcare commercial intelligence. Its SaaS-based healthcare commercial intelligence platform is designed to provide comprehensive and accurate information on the healthcare ecosystem in the U.S. The platform uses deep analytics and data science to help customers develop data-driven strategic decisions, such as finding new markets to enter, building comprehensive go-to-market strategies, accessing tactical information to help target the right decision makers, and improving win rates with detailed contextual information. The company derives substantially all of its revenue from the sale of subscription fees for access to its platform and stand-ready support. Geographically, it derives a majority of its revenue from the United States.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.